|Wednesday, 8 May 2019, 08:37 HKT/SGT|
TOKYO, May 8, 2019 - (JCN Newswire) - Eisai Co., Ltd. and the UK Dementia Research Institute (UK DRI) announced today the launch of a joint post-doctoral programme to support the advancement of novel dementia research. This first-of-its-kind industry collaboration for the UK DRI aims to deliver innovative research that may translate into improvements in diagnosis, treatment and prevention of all types of dementia.
There are an estimated approximately 50 million dementia patients worldwide. As the ageing of the global population gathers pace, the number of dementia patients worldwide is expected to follow this trend, with the total number of people with dementia projected to reach 82 million in 2030 and 152 million in 2050.(1)
To combat this global issue the UK DRI draws together world-leading expertise into a single national institute that conducts research into all aspects of dementia including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, vascular dementia, and Huntington's disease. Under this joint programme, a grant will be provided to post-doctoral researchers engaged in dementia research from 2019 to 2023.
Researchers will benefit from both the UK DRI's state-of-the-art research facilities and Eisai's drug discovery and translational expertise, and will support the work of the organisation in striving to elucidate novel drug discovery targets and mechanisms, develop novel dementia models, and accelerate the linkage of these research results to diagnostics, treatment and care.
"This collaboration is a wonderful example of UK DRI's desire to work with industry for the greater good of dementia science and patient outcomes. We are grateful for the investment and partnership of Eisai, and indeed for the work of all the dedicated researchers trying to move to new frontiers in conquering dementia. We look forward to seeing more fresh thinking on dementia, and to welcoming our colleagues at Eisai to the UK DRI community of ideas and energy," said Dr. Adrian Ivinson, UK DRI Director and COO.
"Eisai is delighted to be able to initiate this joint programme with the UK DRI, the world's largest dementia research institute." said Dr. Teiji Kimura, Chief Discovery Officer of the Eisai Neurology Business Group. "As the UK DRI's first joint programme with a private company, this programme is a highly unique attempt to provide an environment in which post-doctorate researchers engaged in the world's latest dementia research in the UK will be able to demonstrate the full potential of their capabilities. Under this programme, we hope to realize groundbreaking ideas that can be connected with dementia treatment."
Eisai has been conducting research on neurodegenerative diseases in the UK since 1990. In 2012 the company began a research collaboration with University College London (UCL) which will run until 2023 and was established as part of the company's 'Open Innovation' strategy to collaborate with leading researchers and translate new research findings into innovative treatments for patients with neurodegenerative diseases.
About the UK Dementia Research Institute (UK DRI)
Funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, the UK DRI draws world-leaders in dementia research into a single national institute. University College London (UCL) is home to the operational headquarters of the UK DRI and forms the hub for research activities across the six national research centres, which are at UCL, the University of Cambridge, Cardiff University, the University of Edinburgh, Imperial College London and King's College London. By convening world-class dementia researchers to bring about ground-breaking approaches to dementia defined by close collaboration and access to exceptional research resources, the UK DRI aims to find better ways to care for patients.
(1) Alzheimer's Disease International. World Alzheimer Report 2018. https://www.alz.co.uk/research/world-report-2018 (Last accessed March 2019).
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Eisai Co., Ltd.
Public Relations Department
UK Dementia Research Institute
Tel: +44 (0)20 3108 6853
May 8, 2019 08:37 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|May 17, 2019 15:34 HKT/SGT|
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets|
|May 16, 2019 07:37 HKT/SGT|
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting|
|May 10, 2019 12:34 HKT/SGT|
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan|
|May 10, 2019 11:55 HKT/SGT|
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401|
|May 9, 2019 11:33 HKT/SGT|
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions|
|May 9, 2019 11:06 HKT/SGT|
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform|
|May 1, 2019 08:09 HKT/SGT|
Eisai Buys Out Purdue Rights to End Collaboration|
|Apr 24, 2019 16:53 HKT/SGT|
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting|
|Apr 24, 2019 08:36 HKT/SGT|
Eisai Selected as Competitive ICT Strategy Company for 2019|
|Apr 8, 2019 13:06 HKT/SGT|
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090|
|More news >>|